Multimodal strategies integrating RMT, stimuli-responsive carriers, and CRISPRbased gene delivery may collectively overcome the translational gap that single-platform approaches have consistently failed to bridge.
Abstract
The blood-brain barrier (BBB) is critical in CNS pharmacotherapy; it blocks the entry of 98 per cent of small-molecule compounds and almost all macromolecules into the brain parenchyma via tight junction complexes, efflux transporter action, and enzymatic breakdown. This review focuses on the mechanistic basis of BBB resistance and analyses the current landscape of new drug delivery systems developed to overcome this barrier. We elaborate on polymeric nanocarriers, lipid-based nanocarriers, exosomes, dendrimers, and metallic nanoparticles, including surface engineering, the possibility of receptor-mediated transcytosis via transferrin, LRP1, and glucose transporter receptors, and known preclinical efficacy in glioblastoma, Alzheimer's disease, and Parkinson's disease. Non-invasive delivery through the nose is evaluated as intranasal delivery because it utilises olfactory and trigeminal receptors to circumvent systemic delivery. BBB modulation mediated by focused ultrasound is mentioned as one of the physical adjuncts to enhance CNS penetration. Clinical translation is poor, even where the preclinical data are positive. Most late-stage failures can be attributed to protein corona formation, anti-PEG immunogenicity, interpatient heterogeneity in the BBB, and manufacturing scalability. These obstacles are critically evaluated with the help of recent clinical trial evidence, where preclinical models cannot be used as predictors of human outcomes. In the future, AI-based nanocarrier design, machine-learning-driven prediction of BBB permeability, and patient-centred nanomedicine platforms will provide a viable pathway to customised CNS therapeutic approaches. Multimodal strategies integrating RMT, stimuli-responsive carriers, and CRISPRbased gene delivery may collectively overcome the translational gap that single-platform approaches have consistently failed to bridge.
This review critically evaluates recent advances in nanoparticle-mediated BBB targeting, focusing particularly on in vivo findings, and critically discusses the major barriers to clinical translation, including biosafety, manufacturing, and regulatory challenges.
A. Al-allaq, H. A. Hassan, Hidayet Hi̇dayet et al.· Micro· 0 citations
Overall, nanocarrier-assisted nose-to-brain drug delivery represents a transformative platform for the management of central nervous system disorders and has the potential to overcome the limitations of conventional drug delivery systems and improve therapeutic outcomes for a wide range of neurological diseases.
Alpana, H. Dewangan· Current Nanomedicine· 0 citations
Intranasal drug delivery represents a rapidly evolving and promising platform for targeted CNS therapeutics, offering a non-invasive approach with improved patient compliance and enhanced brain targeting, with particular emphasis on emerging technologies designed to improve CNS targeting and therapeutic efficacy.
Sakshi Chouhan, A. Parashar, Trapti Mahajan et al.· Current Pharmacology Reports· 0 citations
INTRODUCTION
The blood-brain barrier (BBB) restricts drug entry into the CNS, with most therapeutics showing < 1% brain penetration, limiting efficacy in neurodegenerative diseases.
AREAS COVERED
Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain b...
Daowei Huang, Roujun Lu, Rui-Jing Tang et al.· Expert Opinion on Therapeuti...· 0 citations
Endogenous cell-mediated transport (CMT) represents a superior strategy for traversing the blood-brain barrier in ischemic stroke, enabling the attainment of therapeutic drug concentrations at the lesion site while simultaneously mitigating systemic toxicity.
S. Nirala, Shu-Yu Wu, Ahmed Hammad et al.· Current Neuropharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.